

Thomas Berg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7182867/publications.pdf>

Version: 2024-02-01

342
papers

31,535
citations

6613

79
h-index

4885

168
g-index

356
all docs

356
docs citations

356
times ranked

23091
citing authors

#	ARTICLE	IF	CITATIONS
1	EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology, 2017, 67, 370-398.	3.7	3,803
2	IL28B is associated with response to chronic hepatitis C interferon- α and ribavirin therapy. Nature Genetics, 2009, 41, 1100-1104.	21.4	1,808
3	Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. New England Journal of Medicine, 2005, 352, 2682-2695.	27.0	1,465
4	Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology, 2010, 138, 1338-1345.e7.	1.3	1,056
5	ABT-450/râ€“Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis. New England Journal of Medicine, 2014, 370, 1973-1982.	27.0	834
6	Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology, 2001, 33, 1080-1086.	7.3	826
7	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	13.7	818
8	Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus Ribavirin. Gastroenterology, 2006, 130, 1086-1097.	1.3	500
9	A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nature Genetics, 2015, 47, 1443-1448.	21.4	435
10	Peginterferon- α -2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C. Gastroenterology, 2005, 129, 522-527.	1.3	425
11	Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C. New England Journal of Medicine, 2007, 357, 2227-2236.	27.0	420
12	Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Reports, 2020, 2, 100113.	4.9	378
13	Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nature Genetics, 2008, 40, 78-82.	21.4	369
14	Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology, 2004, 40, 1421-1425.	7.3	341
15	Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. Journal of Hepatology, 2004, 41, 830-836.	3.7	328
16	Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology, 2010, 51, 73-80.	7.3	303
17	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	3.7	282
18	Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology, 2006, 44, 318-325.	7.3	278

#	ARTICLE	IF	CITATIONS
19	Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. <i>Hepatology</i> , 2011, 53, 62-72.	7.3	274
20	Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1. <i>Gastroenterology</i> , 2014, 147, 443-452.e5.	1.3	268
21	High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. <i>Hepatology</i> , 2010, 52, 472-479.	7.3	267
22	Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in caucasians. <i>Hepatology</i> , 2011, 53, 86-95.	7.3	252
23	Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. <i>Hepatology</i> , 1998, 27, 254-263.	7.3	250
24	Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. <i>Transplantation</i> , 2004, 77, 226-231.	1.0	250
25	Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy. <i>Hepatology</i> , 2003, 37, 600-609.	7.3	247
26	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 1444-1453.	7.3	239
27	Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients â€“ FINITE study. <i>Journal of Hepatology</i> , 2017, 67, 918-924.	3.7	230
28	Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study. <i>Hepatology</i> , 2006, 43, 250-256.	7.3	229
29	Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 4129-4140.	8.2	227
30	Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy. <i>Gastroenterology</i> , 2009, 136, 1618-1628.e2.	1.3	225
31	Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2016, 64, 773-780.	3.7	223
32	Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. <i>Hepatology</i> , 2005, 42, 724-731.	7.3	221
33	A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. <i>Nature Genetics</i> , 2006, 38, 668-673.	21.4	220
34	Simeprevir Increases Rate of Sustained Virologic Response Among Treatment-Experienced Patients With HCV Genotype-1 Infection: A Phase IIb Trial. <i>Gastroenterology</i> , 2014, 146, 430-441.e6.	1.3	217
35	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 875-886.e6.	4.4	217
36	Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. <i>Gastroenterology</i> , 2017, 153, 113-122.	1.3	215

#	ARTICLE	IF	CITATIONS
37	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Journal of Hepatology, 2020, 72, 539-557.	3.7	208
38	Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology, 2015, 61, 66-76.	7.3	204
39	Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. Journal of Hepatology, 2011, 54, 415-421.	3.7	202
40	Viscoelasticity-based Staging of Hepatic Fibrosis with Multifrequency MR Elastography. Radiology, 2010, 257, 80-86.	7.3	198
41	Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology, 2002, 35, 1528-1535.	7.3	188
42	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut, 2015, 64, 1289-1295.	12.1	178
43	First evidence for an association of a functional variant in the microRNA-510 target site of the serotonin receptor-type 3E gene with diarrhea predominant irritable bowel syndrome. Human Molecular Genetics, 2008, 17, 2967-2977.	2.9	173
44	Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer, 2015, 121, 3631-3638.	4.1	173
45	Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. Journal of Hepatology, 2005, 42, 793-798.	3.7	170
46	Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut, 2013, 62, 760-765.	12.1	159
47	Interferon-Î rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nature Communications, 2015, 6, 6422.	12.8	156
48	Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology, 2011, 54, 443-451.	7.3	150
49	Antifibrotic Effects of CXCL9 and Its Receptor CXCR3 in Livers of Mice and Humans. Gastroenterology, 2009, 137, 309-319.e3.	1.3	149
50	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	3.7	149
51	Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. Hepatology, 2007, 45, 864-869.	7.3	139
52	Therapeutic Vaccination of Chronic Hepatitis C Nonresponder Patients With the Peptide Vaccine IC41. Gastroenterology, 2008, 134, 1385-1395.e1.	1.3	138
53	Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: Response and psychiatric side effects. Hepatology, 2007, 46, 991-998.	7.3	134
54	Peginterferon-Î2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C. Gastroenterology, 2005, 129, 522-527.	1.3	133

#	ARTICLE	IF	CITATIONS
55	Tenofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated Patients With Chronic-Hepatitis B Virus Infection. <i>Gastroenterology</i> , 2010, 139, 1207-1217.e3.	1.3	133
56	Interferon- γ , but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. <i>Blood</i> , 2003, 101, 259-264.	1.4	131
57	Non-Invasive Assessment of Hepatic Steatosis in Patients with NAFLD Using Controlled Attenuation Parameter and 1H-MR Spectroscopy. <i>PLoS ONE</i> , 2014, 9, e91987.	2.5	130
58	Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. <i>JHEP Reports</i> , 2020, 2, 100169.	4.9	120
59	The Etiology, Diagnosis and Prevention of Liver Cirrhosis. <i>Deutsches A&#x0308;rztblatt International</i> , 2013, 110, 85-91.	0.9	119
60	Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. <i>Hepatology</i> , 2010, 51, 1127-1136.	7.3	115
61	Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study. <i>Journal of Hepatology</i> , 2012, 56, 520-526.	3.7	114
62	Computed Tomographyâ€“Guided High-Dose-Rate Brachytherapy in Hepatocellular Carcinoma: Safety, Efficacy, and Effect on Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 172-179.	0.8	111
63	The PNPLA3 rs738409 148M/M Genotype Is a Risk Factor for Liver Cancer in Alcoholic Cirrhosis but Shows No or Weak Association in Hepatitis C Cirrhosis. <i>PLoS ONE</i> , 2011, 6, e27087.	2.5	108
64	IL28B, HLA-C, and KIR Variants Additively Predict Response to Therapy in Chronic Hepatitis C Virus Infection in a European Cohort: A Cross-Sectional Study. <i>PLoS Medicine</i> , 2011, 8, e1001092.	8.4	107
65	Mutations in the Protein Kinaseâ€“Binding Domain of the NS5A Protein in Patients Infected with Hepatitis C Virus Type 1a Are Associated with Treatment Response. <i>Journal of Infectious Diseases</i> , 2000, 181, 432-441.	4.0	106
66	Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. <i>Journal of Hepatology</i> , 2011, 54, 1114-1122.	3.7	105
67	Computational methods for the design of effective therapies against drug resistant HIV strains. <i>Bioinformatics</i> , 2005, 21, 3943-3950.	4.1	103
68	Acoustic radiation force impulse imaging (ARFI) for non-invasive detection of liver fibrosis: examination standards and evaluation of interlobe differences in healthy subjects and chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 1458-1467.	1.5	102
69	Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2011, 140, 1990-1999.	1.3	102
70	Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2â€“6: TMC435-C202, a phase IIa, open-label study. <i>Journal of Hepatology</i> , 2012, 56, 1247-1253.	3.7	98
71	The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon- γ 2b and ribavirin in patients with HBV/HCV co-infection. <i>Journal of Hepatology</i> , 2008, 49, 688-694.	3.7	92
72	A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. <i>Journal of Hepatology</i> , 2007, 47, 203-211.	3.7	90

#	ARTICLE	IF	CITATIONS
73	Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients. <i>Journal of Virology</i> , 2013, 87, 6172-6181.	3.4	88
74	IFN- γ 3, not IFN- γ 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017, 49, 795-800.	21.4	86
75	Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 497-506.	9.1	84
76	Treatment of Patients with Recurrent Hepatitis C after Liver Transplantation with Peginterferon Alfa-2B Plus Ribavirin. <i>Transplantation</i> , 2006, 82, 43-47.	1.0	83
77	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016, 64, 34-46.	7.3	83
78	Agreement between the Sunnybrook, House-Brackmann, and Yanagihara Facial Nerve Grading Systems in Bell's Palsy. <i>Otology and Neurotology</i> , 2004, 25, 1020-1026.	1.3	82
79	Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis. <i>American Journal of Gastroenterology</i> , 2018, 113, 1475-1483.	0.4	82
80	Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2014, 60, 715-722.	3.7	81
81	Evaluation of liver disease progression in the German hepatitis C virus (1b)-contaminated anti-D cohort at 35 years after infection. <i>Hepatology</i> , 2014, 59, 49-57.	7.3	81
82	Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. <i>Hepatology</i> , 2002, 36, 507-508.	7.3	79
83	Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. <i>Journal of Hepatology</i> , 1999, 30, 1004-1013.	3.7	77
84	Randomized, Double-Blind, Placebo-Controlled Trial of Interferon Alfa2a With and Without Amantadine as Initial Treatment for Chronic Hepatitis C. <i>Hepatology</i> , 2000, 32, 835-841.	7.3	77
85	Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. <i>Hepatology</i> , 2020, 72, 88-102.	7.3	76
86	A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. <i>Journal of Hepatology</i> , 2009, 50, 370-376.	3.7	75
87	Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. <i>Hepatology</i> , 2012, 55, 1700-1710.	7.3	75
88	Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. <i>Journal of Hepatology</i> , 2015, 62, 1256-1264.	3.7	75
89	Potentially inappropriate liver transplantation in the era of the "sickest first" policy: A search for the upper limits. <i>Journal of Hepatology</i> , 2018, 68, 798-813.	3.7	74
90	Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. <i>Hepatology</i> , 2018, 68, 839-847.	7.3	72

#	ARTICLE	IF	CITATIONS
91	The toll-like receptor 2 (TLR2) 196 to 174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. International Journal of Cancer, 2012, 130, 1470-1475.	5.1	71
92	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. Journal of Hepatology, 2020, 73, 1037-1045.	3.7	69
93	Granulocyte-colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicenter randomized trial (GRAFT study). Journal of Hepatology, 2021, 75, 1346-1354.	3.7	69
94	Responsiveness to interferon alpha treatment in patients with chronic hepatitis C coinfecting with hepatitis G virus. Journal of Hepatology, 1996, 25, 763-768.	3.7	68
95	Induction of Interleukin-6 by Hepatitis C Virus Core Protein in Hepatitis C-Associated Mixed Cryoglobulinemia and B-Cell Non-Hodgkin's Lymphoma. Clinical Cancer Research, 2006, 12, 4491-4498.	7.0	68
96	Isoforms of Retinol binding protein 4 (RBP4) are increased in chronic diseases of the kidney but not of the liver. Lipids in Health and Disease, 2008, 7, 29.	3.0	68
97	PREOPERATIVE ANTIVIRAL TREATMENT AND POSTOPERATIVE PROPHYLAXIS IN HBV-DNA POSITIVE PATIENTS UNDERGOING LIVER TRANSPLANTATION. Transplantation, 2001, 72, 1381-1385.	1.0	68
98	Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transplantation, 2011, 17, 289-298.	2.4	67
99	A polymorphism in the Irisin-encoding gene (FND5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. Journal of Hepatology, 2019, 70, 494-500.	3.7	67
100	The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. Journal of Hepatology, 2008, 48, 208-215.	3.7	66
101	Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver International, 2011, 31, 1574-1588.	3.9	66
102	Differential priming of CD8 and CD4 T-cells in animal models of autoimmune hepatitis and cholangitis. Hepatology, 2007, 46, 1155-1165.	7.3	65
103	MMF and Calcineurin Taper in Recurrent Hepatitis C After Liver Transplantation: Impact on Histological Course. American Journal of Transplantation, 2005, 5, 406-411.	4.7	64
104	Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. Aids, 2006, 20, 1951-1954.	2.2	64
105	FibroGENE: A gene-based model for staging liver fibrosis. Journal of Hepatology, 2016, 64, 390-398.	3.7	64
106	Hepatitis GBV-C sequences in patients infected with HCV contaminated anti-D immunoglobulin and among i.v. drug users in Germany. Journal of Hepatology, 1996, 25, 385-389.	3.7	63
107	Pregnancy in primary sclerosing cholangitis. Gut, 2011, 60, 1117-1121.	12.1	63
108	The HLA-DRB1/HLA-DQB1 Genotype Affects the Natural Course of Hepatitis C Virus (HCV) Infection and Is Associated with HLA-DQB1-Restricted Recognition of an HCV-Derived Peptide by Interferon-γ-Secreting Human CD8+T Cells. Journal of Infectious Diseases, 2009, 200, 1397-1401.	4.0	62

#	ARTICLE	IF	CITATIONS
109	Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. <i>Trends in Molecular Medicine</i> , 2010, 16, 277-286.	6.7	62
110	Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. <i>Genome Medicine</i> , 2011, 3, 57.	8.2	62
111	Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. <i>Hepatology</i> , 2000, 32, 1386-1395.	7.3	61
112	Hepatocellular carcinoma: computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of large (5-7Åcm) and very large (>7Åcm) tumours. <i>European Radiology</i> , 2012, 22, 1101-1109.	4.5	61
113	Gastrointestinal complications of obesity: Non-alcoholic fatty liver disease (NAFLD) and its sequelae. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2013, 27, 195-208.	4.7	61
114	Triple therapy with amantadine in treatment-naïve patients with chronic hepatitis C: A placebo-controlled trial. <i>Hepatology</i> , 2003, 37, 1359-1367.	7.3	60
115	A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C. <i>PLoS ONE</i> , 2012, 7, e40159.	2.5	60
116	Rapid Viral Response of Once-Daily Tmc435 plus Pegylated Interferon/Ribavirin in Hepatitis C Genotype-1 Patients: A Randomized Trial. <i>Antiviral Therapy</i> , 2011, 16, 1021-1033.	1.0	59
117	Escitalopram for the Prevention of Peginterferon-Associated Depression in Hepatitis C Virus-Infected Patients Without Previous Psychiatric Disease. <i>Annals of Internal Medicine</i> , 2012, 157, 94.	3.9	59
118	Genetic Analyses Reveal a Role for Vitamin D Insufficiency in HCV-Associated Hepatocellular Carcinoma Development. <i>PLoS ONE</i> , 2013, 8, e64053.	2.5	59
119	T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 77, 397-409.	3.7	59
120	Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment-induced recovery from hepatitis C virus infection. <i>Journal of Hepatology</i> , 2004, 41, 652-658.	3.7	56
121	Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2018, 218, 1066-1074.	4.0	56
122	Angiopoietin-2 Serum Levels Are Elevated in Patients With Liver Cirrhosis and Hepatocellular Carcinoma. <i>American Journal of Gastroenterology</i> , 2007, 102, 2471-2481.	0.4	55
123	Prevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients. <i>Journal of Hepatology</i> , 2014, 60, 928-933.	3.7	55
124	Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. <i>Hepatology</i> , 2009, 50, 369-377.	7.3	53
125	Increased T-Helper 2 Cytokines in Bile From Patients With IgG4-Related Cholangitis Disrupt the Tight Junction-Associated Biliary Epithelial Cell Barrier. <i>Gastroenterology</i> , 2013, 144, 1116-1128.	1.3	53
126	Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. <i>Hepatology</i> , 2015, 62, 111-117.	7.3	52

#	ARTICLE	IF	CITATIONS
127	Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. <i>Journal of Hepatology</i> , 2017, 66, 11-18.	3.7	52
128	Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters. <i>Journal of Hepatology</i> , 1997, 26, 484-491.	3.7	51
129	Association of CTLA4 single nucleotide polymorphisms with viral but not autoimmune liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 947-951.	1.6	51
130	Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis. <i>Human Molecular Genetics</i> , 2014, 23, 3883-3890.	2.9	50
131	A clinical and virological study of hepatitis C virus-related cryoglobulinemia in Germany. <i>Journal of Hepatology</i> , 1998, 29, 375-384.	3.7	49
132	Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. <i>Hepatology</i> , 2011, 54, 1538-1546.	7.3	49
133	Intrahepatic cholestasis in common chronic liver diseases. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1069-1083.	3.4	49
134	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e784-e793.	4.4	49
135	Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. <i>Gastroenterology</i> , 2003, 124, 586-587.	1.3	49
136	GB VIRUS C INFECTION IN PATIENTS WITH CHRONIC HEPATITIS B AND C BEFORE AND AFTER LIVER TRANSPLANTATION. <i>Transplantation</i> , 1996, 62, 711-714.	1.0	49
137	Non-Invasive Evaluation of Cystic Fibrosis Related Liver Disease in Adults with ARFI, Transient Elastography and Different Fibrosis Scores. <i>PLoS ONE</i> , 2012, 7, e42139.	2.5	49
138	An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318.	3.7	48
139	Gender-dependent association of CTLA4 polymorphisms with resolution of hepatitis C virus infection. <i>Journal of Hepatology</i> , 2007, 46, 372-380.	3.7	46
140	The times they are a-changing â€“ A refined proposal for finite HBV nucleos(t)ide analogue therapy. <i>Journal of Hepatology</i> , 2021, 75, 474-480.	3.7	46
141	Rapid Suppression of Hepatitis C Viremia Induced by Intravenous Silibinin Plus Ribavirin. <i>Gastroenterology</i> , 2009, 137, 390-391.	1.3	45
142	Fibrosis Progression in Hepatitis C Positive Liver Recipients After Sustained Virologic Response to Antiviral Combination Therapy (Interferon???Ribavirin Therapy). <i>Transplantation</i> , 2007, 83, 351-353.	1.0	44
143	Chances and limitations of nonâ€“invasive tests in the assessment of liver fibrosis in liver transplant patients. <i>Clinical Transplantation</i> , 2010, 24, 652-659.	1.6	44
144	Dynamics of GB Virus C viremia early after orthotopic liver transplantation indicates extrahepatic tissues as the predominant site of GB virus C replication. <i>Hepatology</i> , 1999, 29, 245-249.	7.3	43

#	ARTICLE	IF	CITATIONS
145	High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients. PLoS ONE, 2012, 7, e41206.	2.5	43
146	The impact of elevated serum IgG4 levels in patients with primary sclerosing cholangitis. Digestive and Liver Disease, 2014, 46, 903-908.	0.9	42
147	Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. Clinical Infectious Diseases, 2021, 72, 202-211.	5.8	41
148	Effects of the CCR5-Δ32 mutation on antiviral treatment in chronic hepatitis C. Journal of Hepatology, 2003, 39, 245-252.	3.7	40
149	Management of Chronic Hepatitis B: Status and Challenges beyond Treatment Guidelines. Seminars in Liver Disease, 2010, 30, 361-377.	3.6	40
150	Improved Responses to Pegylated Interferon Alfa-2b and Ribavirin by Individualizing Treatment for 24-72 Weeks. Gastroenterology, 2011, 141, 1656-1664.	1.3	40
151	The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. Hepatology, 2009, 49, 775-780.	7.3	39
152	Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. Journal of Hepatology, 2004, 40, 478-483.	3.7	38
153	Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? Hepatology, 2004, 39, 1456-1457.	7.3	37
154	Soluble Urokinase Plasminogen Activator Receptor is Associated With Progressive Liver Fibrosis in Hepatitis C Infection. Journal of Clinical Gastroenterology, 2012, 46, 334-338.	2.2	37
155	A systematic review and meta-analysis of HCV clearance. Liver International, 2017, 37, 1431-1445.	3.9	37
156	Occurrence and clinical outcome of lamivudine-resistant hepatitis B infection after liver transplantation. Liver Transplantation, 2001, 7, 976-982.	2.4	36
157	Haplotype-tagging RANTES gene variants influence response to antiviral therapy in chronic hepatitis C. Hepatology, 2004, 40, 327-334.	7.3	36
158	Less can be more: A finite treatment approach for HBeAg-negative chronic hepatitis B. Hepatology, 2018, 68, 397-400.	7.3	36
159	Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfecting patients. Hepatology, 2007, 46, 1016-1025.	7.3	35
160	Non-invasive evaluation of hepatic manifestation in Wilson disease with transient elastography, ARFI, and different fibrosis scores. Scandinavian Journal of Gastroenterology, 2012, 47, 1353-1361.	1.5	35
161	A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. Journal of Hepatology, 2014, 61, 1073-1079.	3.7	35
162	Prevention of Hepatitis B Recurrence after Liver Transplantation. Transplantation, 2005, 80, S120-S124.	1.0	34

#	ARTICLE	IF	CITATIONS
163	HIV-GRADE: A Publicly Available, Rules-Based Drug Resistance Interpretation Algorithm Integrating Bioinformatic Knowledge. Intervirology, 2012, 55, 102-107.	2.8	34
164	Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. Hepatology, 2015, 61, 460-470.	7.3	33
165	Molecular quantification and differentiation of Candida species in biological specimens of patients with liver cirrhosis. PLoS ONE, 2018, 13, e0197319.	2.5	33
166	Comparative sequence analysis of the core- and NS5-region of hepatitis C virus from tumor and adjacent non-tumor tissue. Journal of Medical Virology, 2001, 63, 128-134.	5.0	32
167	Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1. Hepatology, 2003, 38, 1592-1592.	7.3	32
168	Distinct, alcohol-modulated effects of PNPLA3 genotype on progression of chronic hepatitis C. Journal of Hepatology, 2011, 55, 732-733.	3.7	32
169	Hepatitis C virus (HCV)-infection and oral lichen planus. Journal of Hepatology, 1998, 29, 1034-1035.	3.7	31
170	CC chemokine receptor 5 32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia. Journal of Molecular Medicine, 2004, 82, 64-69.	3.9	31
171	Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation. Liver Transplantation, 2006, 12, 644-651.	2.4	31
172	Impact of the MELD allocation after its implementation in liver transplantation. Scandinavian Journal of Gastroenterology, 2011, 46, 941-948.	1.5	31
173	Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy. Pharmacogenetics and Genomics, 2011, 21, 289-296.	1.5	31
174	The detection of HBsAg mutants expressed in vitro using two different quantitative HBsAg assays. Journal of Clinical Virology, 2012, 54, 279-281.	3.1	31
175	DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection. Hepatology, 2016, 63, 418-427.	7.3	31
176	Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBsAg-negative chronic hepatitis B. Liver International, 2018, 38, 90-96.	3.9	31
177	Combination of G-CSF and a TLR4 inhibitor reduce inflammation and promote regeneration in a mouse model of ACLF. Journal of Hepatology, 2022, 77, 1325-1338.	3.7	31
178	Hepatocytes That Express Variants of Cyclophilin A Are Resistant to HCV Infection and Replication. Gastroenterology, 2012, 143, 439-447.e1.	1.3	30
179	Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. Journal of Hepatology, 2002, 37, 843-847.	3.7	29
180	New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C. Gut, 2014, 63, 207-215.	12.1	29

#	ARTICLE	IF	CITATIONS
181	Apolipoprotein E allele frequencies in chronic and self-limited hepatitis C suggest a protective effect of $\epsilon\epsilon$ APOE4 in the course of hepatitis C virus infection. Liver International, 2016, 36, 1267-1274.	3.9	29
182	Low sphingosine-1-phosphate plasma levels are predictive for increased mortality in patients with liver cirrhosis. PLoS ONE, 2017, 12, e0174424.	2.5	29
183	Loss of paraspinal muscle mass is a gender-specific consequence of cirrhosis that predicts complications and death. Alimentary Pharmacology and Therapeutics, 2018, 48, 1271-1281.	3.7	29
184	Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. Hepatology, 2008, 48, 1404-1411.	7.3	28
185	Noninvasive characterization of graft steatosis after liver transplantation. Scandinavian Journal of Gastroenterology, 2015, 50, 224-232.	1.5	28
186	GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection. Journal of Hepatology, 2005, 43, 388-393.	3.7	27
187	Occurrence of a novel DNA virus (TTV) infection in patients with liver diseases and its frequency in blood donors. , 1999, 59, 117-121.		26
188	Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-1a-2a and ribavirin. European Journal of Gastroenterology and Hepatology, 2010, 22, 1303-1307.	1.6	26
189	Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load. Journal of Hepatology, 2017, 67, 237-245.	3.7	26
190	Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion. Journal of Hepatology, 2022, 77, 1670-1689.	3.7	26
191	Genetic variations of the chemokine scavenger receptor D6 are associated with liver inflammation in chronic hepatitis C. Human Immunology, 2008, 69, 861-866.	2.4	25
192	A frequent hypofunctional IRAK2 variant is associated with reduced spontaneous hepatitis C virus clearance. Hepatology, 2015, 62, 1375-1387.	7.3	25
193	Antiviral Treatment of Patients with Recurrent Hepatitis C After Liver Transplantation with Pegylated Interferon. Digestive Diseases and Sciences, 2010, 55, 2063-2069.	2.3	24
194	Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection. Gut, 2017, 66, 1829-1837.	12.1	24
195	Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. JHEP Reports, 2020, 2, 100173.	4.9	24
196	PRETRANSPLANT VIROLOGICAL MARKERS HEPATITIS C VIRUS GENOTYPE AND VIREMIA LEVEL ARE NOT HELPFUL IN PREDICTING INDIVIDUAL OUTCOME AFTER ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation, 1998, 66, 225-228.	1.0	23
197	Interleukin 18 Promoter Variants ($\epsilon\epsilon$ 137G>C and $\epsilon\epsilon$ 607C>A) in Patients with Chronic Hepatitis C: Association with Treatment Response. Journal of Clinical Immunology, 2009, 29, 620-628.	3.8	22
198	Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. United European Gastroenterology Journal, 2018, 6, 213-224.	3.8	22

#	ARTICLE	IF	CITATIONS
199	COVID-19 and the liver – Lessons learned. Liver International, 2021, 41, 1-8.	3.9	22
200	Global impact of the first wave of COVID-19 on liver transplant centers: A multi-society survey (EASL-ESOT/ELITA-ILTS). Journal of Hepatology, 2022, 76, 364-370.	3.7	22
201	DISTINCT ENZYME PROFILES IN PATIENTS WITH CRYPTOGENIC CIRRHOSIS REFLECT HETEROGENEOUS CAUSES WITH DIFFERENT OUTCOMES AFTER LIVER TRANSPLANTATION (OLT): A LONG-TERM DOCUMENTATION BEFORE AND AFTER OLT. Transplantation, 2002, 74, 792-798.	1.0	21
202	Quantitative detection and typing of hepatitis D virus in human serum by real-time polymerase chain reaction and melting curve analysis. Diagnostic Microbiology and Infectious Disease, 2010, 67, 172-179.	1.8	21
203	The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection. Journal of Gastroenterology, 2011, 46, 1427-1436.	5.1	21
204	Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. Journal of Viral Hepatitis, 2020, 27, 610-619.	2.0	21
205	Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. Liver, 2000, 20, 427-436.	0.1	20
206	The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5 Δ 32 mutation. Journal of Hepatology, 2011, 55, 1201-1206.	3.7	20
207	TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients. BMC Cancer, 2012, 12, 85.	2.6	20
208	Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Response in Chronic Hepatitis C. PLoS ONE, 2014, 9, e112592.	2.5	20
209	Efficacy and Safety of Bulevirtide plus Tenofovir Disoproxil Fumarate in Real-World Patients with Chronic Hepatitis B and D Co-Infection. Pathogens, 2022, 11, 517.	2.8	20
210	Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. Transplant International, 2000, 13, 290-296.	1.6	19
211	FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program. Journal of Hepatology, 2011, 54, 227-235.	3.7	19
212	Vitamin D Levels Vary during Antiviral Treatment but Are Unable to Predict Treatment Outcome in HCV Genotype 1 Infected Patients. PLoS ONE, 2014, 9, e87974.	2.5	19
213	Current NAFLD guidelines for risk stratification in diabetic patients have poor diagnostic discrimination. Scientific Reports, 2020, 10, 18345.	3.3	19
214	Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Research, 2021, 185, 104992.	4.1	19
215	Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. Alimentary Pharmacology and Therapeutics, 2021, 53, 314-320.	3.7	19
216	Genetic variation in <i>TERT</i> modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study. Gut, 2023, 72, 381-391.	12.1	19

#	ARTICLE	IF	CITATIONS
217	Hepatitis-C Patients Have Reduced Growth Hormone (GH) Secretion Which Improves During Long-Term Therapy With Pegylated Interferon- α . American Journal of Gastroenterology, 2007, 102, 2724-2731.	0.4	18
218	Influence of the CXCL1 rs4074 A Allele on Alcohol Induced Cirrhosis and HCC in Patients of European Descent. PLoS ONE, 2013, 8, e80848.	2.5	18
219	The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care. JHEP Reports, 2020, 2, 100168.	4.9	18
220	ADDITIONAL INTERFERON ALPHA FOR LAMIVUDINE RESISTANT HEPATITIS B INFECTION AFTER LIVER TRANSPLANTATION: A PRELIMINARY REPORT. Transplantation, 2000, 69, 1739-1742.	1.0	18
221	Reactivation of viral replication after replacement of tenofovir by adefovir. Hepatology, 2005, 42, 239-240.	7.3	17
222	The CXCL1 rs4074 A allele is associated with enhanced CXCL1 responses to TLR2 ligands and predisposes to cirrhosis in HCV genotype 1-infected Caucasian patients. Journal of Hepatology, 2012, 56, 758-764.	3.7	17
223	Sadness and mild cognitive impairment as predictors for interferon-alpha-induced depression in patients with hepatitis C. British Journal of Psychiatry, 2015, 206, 45-51.	2.8	17
224	Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. Drugs and Aging, 2018, 35, 843-857.	2.7	17
225	PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C. PLoS ONE, 2014, 9, e94512.	2.5	17
226	Outcome after liver re-transplantation in patients with recurrent chronic hepatitis C. Transplant International, 2007, 20, 771-778.	1.6	16
227	Treatment of HBV related cirrhosis. Liver International, 2013, 33, 176-181.	3.9	16
228	Persistent Hepatitis G Virus Infection After Neonatal Transfusion. Journal of Pediatric Gastroenterology and Nutrition, 1998, 26, 402-407.	1.8	16
229	No Role of Matrixmetalloproteinase-3 Genetic Promoter Polymorphism 1171 as a Risk Factor for Cirrhosis in Alcoholic Liver Disease. Alcoholism: Clinical and Experimental Research, 2008, 32, 959-965.	2.4	15
230	Evaluation of the transforming growth factor β 1 codon 25 (Arg \rightarrow Pro) polymorphism in alcoholic liver disease. Cytokine, 2008, 42, 18-23.	3.2	15
231	Evolution of Adefovir-Resistant HBV Polymerase Gene Variants after Switching to Tenofovir Disoproxil Fumarate Monotherapy. Antiviral Therapy, 2012, 17, 1049-1058.	1.0	15
232	Management of Infectious Complications Associated with Acute-on-Chronic Liver Failure. Visceral Medicine, 2018, 34, 261-268.	1.3	15
233	A Common Variant of PNPLA3 (p.I148M) Is Not Associated with Alcoholic Chronic Pancreatitis. PLoS ONE, 2012, 7, e29433.	2.5	15
234	Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3. Antiviral Therapy, 2008, 13, 17-22.	1.0	15

#	ARTICLE	IF	CITATIONS
235	Quality control study on the performance of GB virus C/hepatitis G virus PCR. <i>Journal of Hepatology</i> , 1998, 28, 978-984.	3.7	14
236	Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon- α and ribavirin: results from a randomized, placebo-controlled, double-blind trial. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 639-646.	1.6	14
237	Application of Qualitative and Quantitative Real-Time PCR, Direct Sequencing, and Terminal Restriction Fragment Length Polymorphism Analysis for Detection and Identification of Polymicrobial 16S rRNA Genes in Ascites. <i>Journal of Clinical Microbiology</i> , 2014, 52, 1754-1757.	3.9	14
238	Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently \leq normal alanine aminotransferase levels treated with peginterferon α -2a (40KD) plus ribavirin. <i>Liver International</i> , 2008, 28, 61-71.	3.9	13
239	Tailored Treatment for Hepatitis C. <i>Clinics in Liver Disease</i> , 2008, 12, 507-528.	2.1	13
240	Further evidence for the relevance of TLR2 gene variants in spontaneous bacterial peritonitis. <i>Journal of Hepatology</i> , 2012, 56, 1207-1208.	3.7	13
241	Antiviral Therapy of Chronic Hepatitis B. <i>Intervirology</i> , 2014, 57, 171-180.	2.8	13
242	SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α -2a and Ribavirin in Treatment-Naïve Hepatitis C Virus Genotype 1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3429-3436.	3.2	13
243	Influence of Donor Histology on Outcome in Patients Undergoing Transplantation for Hepatitis C. <i>Transplantation</i> , 2007, 84, 144-148.	1.0	12
244	Relevance of endotoxin receptor CD14 and TLR4 gene variants in chronic liver disease. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 584-592.	1.5	12
245	HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection. <i>Journal of Hepatology</i> , 2010, 53, 1022-1028.	3.7	12
246	The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients. <i>Journal of Hepatology</i> , 2007, 47, 348-355.	3.7	11
247	Low-density lipoprotein receptor variants are associated with spontaneous and treatment-induced recovery from hepatitis C virus infection. <i>Infection, Genetics and Evolution</i> , 2009, 9, 847-852.	2.3	11
248	Silibinin in hepatitis C related liver transplantation. <i>Journal of Hepatology</i> , 2011, 54, 592-593.	3.7	11
249	Evaluation of a rapid on-site anti-HCV test as a screening tool for hepatitis C virus infection. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 416-420.	1.6	11
250	Detection of molecular bacterascites in decompensated cirrhosis defines a risk with decreased survival. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1285-1292.	1.6	11
251	Real-World Clinical Management of Patients with Primary Biliary Cholangitis—A Retrospective Multicenter Study from Germany. <i>Journal of Clinical Medicine</i> , 2021, 10, 1061.	2.4	11
252	Copy number variation and expression of exportin-4 associates with severity of fibrosis in metabolic associated fatty liver disease. <i>EBioMedicine</i> , 2021, 70, 103521.	6.1	11

#	ARTICLE	IF	CITATIONS
253	Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B. PLoS ONE, 2013, 8, e67481.	2.5	11
254	Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection. Journal of Hepatology, 2008, 49, 339-345.	3.7	10
255	Do common genetic variants in endotoxin signaling pathway contribute to predisposition to alcoholic liver cirrhosis?. Clinical Chemistry and Laboratory Medicine, 2009, 47, 398-404.	2.3	10
256	Flares during long-term entecavir therapy in chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1882-1887.	2.8	10
257	Effects of granulocyte-colony stimulating factor (G-CSF) on stem cell mobilization in patients with liver failure. European Journal of Internal Medicine, 2016, 36, e37-e39.	2.2	10
258	Hepatitis B Vaccination in Patients with Liver Cirrhosis Evaluated for Liver Transplantation – A Simple Intervention Ensures High Adherence. Annals of Transplantation, 2019, 24, 527-531.	0.9	10
259	Impact of in vivo complement activation and cryoglobulins on graft outcome of HCV-infected renal allograft recipients. Clinical Transplantation, 2004, 18, 7-13.	1.6	9
260	Persistence of a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33 months in the absence of treatment. Aids, 2006, 20, 2231-2233.	2.2	9
261	Elevated concentrations of 15-deoxy- $\Delta^{12,14}$ -prostaglandin J ₂ in chronic liver disease propose therapeutic trials with peroxisome proliferator activated receptor β -inducing drugs. Liver International, 2009, 29, 730-735.	3.9	9
262	The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?. AIDS Research and Therapy, 2011, 8, 7.	1.7	9
263	Bezafibrate maintenance therapy in patients with advanced chronic hepatitis C. European Journal of Gastroenterology and Hepatology, 2013, 25, 594-600.	1.6	9
264	Effect of a bioactive cement on the microbial community in carious dentin after selective caries removal – An in-vivo study. Journal of Dentistry, 2020, 92, 103264.	4.1	9
265	Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. Alimentary Pharmacology and Therapeutics, 2020, 52, 500-512.	3.7	9
266	Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C Registry. Liver International, 2021, 41, 1518-1522.	3.9	9
267	Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation. Transplant International, 2000, 13, 290-296.	1.6	9
268	Demonstration of PDC-E1 subunits as major antigens in the complement-fixing fraction M4 and re-evaluation of PDC-E1-specific antibodies in PBC patients. Liver International, 2006, 26, 846-855.	3.9	8
269	A Duffy antigen receptor for chemokines (DARC) polymorphism that determines pro-fibrotic chemokine serum concentrations is not directly associated with severity of hepatitis C infection. Human Immunology, 2011, 72, 273-277.	2.4	8
270	Association of IFNL3 rs12979860 and rs8099917 with Biochemical Predictors of Interferon Responsiveness in Chronic Hepatitis C Virus Infection. PLoS ONE, 2013, 8, e77530.	2.5	8

#	ARTICLE	IF	CITATIONS
271	Ascitesâ€™ neutrophil function is significantly impaired in patients with decompensated cirrhosis but can be restored by autologous plasma incubation. Scientific Reports, 2016, 6, 37926.	3.3	8
272	Fatal Outcome of Hepatitis A Virus (HAV) Infection in a Traveler with Incomplete HAV Vaccination and Evidence of Rift Valley Fever Virus Infection. Journal of Clinical Microbiology, 2008, 46, 3850-3852.	3.9	7
273	Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: A randomized study. Journal of Hepatology, 2013, 58, 452-459.	3.7	7
274	No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: The ATRACTION study, a phase II randomised trial. Digestive and Liver Disease, 2013, 45, 323-329.	0.9	7
275	Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity. European Journal of Gastroenterology and Hepatology, 2016, 28, 187-192.	1.6	7
276	Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting. European Journal of Gastroenterology and Hepatology, 2018, 30, 280-283.	1.6	7
277	The PNPLA3 I148M variant promotes lipid-induced hepatocyte secretion of CXC chemokines establishing a tumorigenic milieu. Journal of Molecular Medicine, 2019, 97, 1589-1600.	3.9	7
278	Low prevalence of occult hepatitis B virus infection in chronic haemodialysis and kidney transplant patients. Liver International, 2019, 39, 263-270.	3.9	7
279	Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). Scandinavian Journal of Gastroenterology, 2020, 55, 706-711.	1.5	7
280	Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH,) Tj ETQq0 0 0 rgt /Overlock 10 Tf		
281	IMMUTACE: A biomarker-orientated phase II, single-arm, open-label AIO study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma (HCC; AIO-HEP-0217)â€™ Updated efficacy results.. Journal of Clinical Oncology, 2022, 40, 4116-4116.	1.6	7
282	Triple therapy with amantadine sulphate plus ribavirin and interferon-alpha in previously untreated patients with chronic hepatitis C: results of a double-blind, placebo-controlled trial. Journal of Hepatology, 2002, 36, 3.	3.7	6
283	Prediction of spontaneous viral clearance in acute hepatitis C by viral load measurements. Hepatology, 2003, 37, 1495-1496.	7.3	6
284	Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial. Hepatology International, 2014, 8, 517-526.	4.2	6
285	Lowâ€™density lipoprotein and other predictors of response with telaprevirâ€™based therapy in treatmentâ€™experienced <scp>HCV</scp> genotype 1 patients: <scp>REALIZE</scp> study. Liver International, 2015, 35, 448-454.	3.9	6
286	A genetic variant in tollâ€™like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis. Liver International, 2021, 41, 2139-2148.	3.9	6
287	Oxidized Low-Density Lipoprotein Is a Novel Predictor of Interferon Responsiveness in Chronic Hepatitis C Infection. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 285-294.e1.	4.5	5
288	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. Open Forum Infectious Diseases, 2018, 5, ofy248.	0.9	5

#	ARTICLE	IF	CITATIONS
289	Molecular characterization of intact cell-derived and cell-free bacterial DNA from carious dentine samples. <i>Journal of Microbiological Methods</i> , 2019, 158, 33-43.	1.6	5
290	Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection. <i>Journal of Clinical Medicine</i> , 2019, 8, 2101.	2.4	5
291	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100290.	4.9	5
292	Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register). <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1424-1431.	1.6	5
293	Role of tenofovir in the treatment of chronic HBV infection. <i>Future Virology</i> , 2008, 3, 207-220.	1.8	4
294	Reply to: "Underestimation of occult hepatitis C virus infection in chronic haemodialysis and kidney transplant patients". <i>Journal of Hepatology</i> , 2014, 61, 1185-1186.	3.7	4
295	Hepcidin as a predictor of treatment response in chronic hepatitis C infection. <i>Hepatology</i> , 2014, 59, 1648-1648.	7.3	4
296	A Preliminary Study on the Relationship between Platelet Serotonin Transporter Functionality, Depression, and Fatigue in Patients with Untreated Chronic Hepatitis C. <i>Depression Research and Treatment</i> , 2014, 2014, 1-12.	1.3	4
297	Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties. <i>Hepatology</i> , 2015, 62, 726-736.	7.3	4
298	Evaluation of muscarinic acetylcholine receptor type 3 gene polymorphisms in patients with primary biliary cholangitis and primary sclerosing cholangitis. <i>Hepatology Research</i> , 2020, 50, 321-329.	3.4	4
299	Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver. <i>Cells</i> , 2020, 9, 1817.	4.1	4
300	Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease. <i>Biomedicines</i> , 2022, 10, 451.	3.2	4
301	Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , 2011, 53, 1111-1114.	5.8	3
302	Escitalopram for the Prevention of Peginterferon- α 2a-Associated Depression. <i>Annals of Internal Medicine</i> , 2013, 158, 140.	3.9	3
303	Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015. <i>Journal of Hepatology</i> , 2016, 64, 1428-1445.	3.7	3
304	Detection of Inflammatory and Homeostasis Biomarkers after Selective Removal of Carious Dentin: An In Vivo Feasibility Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 1003.	2.4	3
305	Hepatocellular Carcinoma Prevention by Aspirin: Are Platelets the Link?. <i>Hepatology Communications</i> , 2021, 5, 2151-2152.	4.3	3
306	Influence of gender on cytokine induced depression and treatment. <i>Journal of Affective Disorders</i> , 2021, 292, 766-772.	4.1	3

#	ARTICLE	IF	CITATIONS
307	Clinical implications of hepatic structure and function evaluation based on vibration-controlled transient elastography and liver maximum function capacity test in patients with nonalcoholic fatty liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 686-692.	1.6	3
308	Hepatic Hedgehog Signaling Participates in the Crosstalk between Liver and Adipose Tissue in Mice by Regulating FGF21. <i>Cells</i> , 2022, 11, 1680.	4.1	3
309	Increased mortality after liver transplantation for hepatocellular carcinoma in hepatitis B-associated cirrhosis. <i>Transplant International</i> , 2003, 16, 33-36.	1.6	2
310	New perspectives in the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2005, 41, 1402-1406.	7.3	2
311	Evaluation of Angiotensinogen c.1-44G>A and p.M268T Variants as Risk Factors for Fibrosis Progression in Chronic Hepatitis C and Liver Diseases of Various Etiologies. <i>Genetic Testing and Molecular Biomarkers</i> , 2009, 13, 407-414.	0.7	2
312	Influence of alpha-1 antitrypsin heterozygosity on treatment efficacy of HCV combination therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 808-812.	1.6	2
313	Impact of cohort size and host factors on combined analysis of interleukin 28B rs12979860 and rs8099917 in hepatitis C virus infection. <i>Hepatology</i> , 2013, 57, 416-417.	7.3	2
314	Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. <i>Annals of Hepatology</i> , 2013, 12, 190-198.	1.5	2
315	Long-term efficacy of interferon alpha treatment in chronic hepatitis C. <i>Journal of Hepatology</i> , 1998, 29, 511-512.	3.7	1
316	Reply:. <i>Hepatology</i> , 2005, 42, 1459-1460.	7.3	1
317	Corrigendum to: "FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program" [J Hepatol 2011;54:227-235]. <i>Journal of Hepatology</i> , 2013, 59, 914.	3.7	1
318	Reply to: "Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients" [J Hepatol 2018;68:1104-1105]. <i>Journal of Hepatology</i> , 2018, 68, 1104-1105.	3.7	1
319	Antibacterial effect of a brominated self-etch adhesive on carious dentin - An in vivo study. <i>Journal of Dentistry</i> , 2021, 105, 103555.	4.1	1
320	Hepatitis B Vaccination in End-Stage Pulmonary Disease Patients Evaluated for Lung Transplantation: A Retrospective Single-Center Evaluation. <i>Annals of Transplantation</i> , 2016, 21, 368-372.	0.9	1
321	Intrahepatic cholestasis of pregnancy resistant to both therapeutic plasma exchange and albumin dialysis. <i>BMJ Case Reports</i> , 2022, 15, e246318.	0.5	1
322	Surrogate Markers for Hepatitis B Virus Covalently Closed Circular DNA. <i>Seminars in Liver Disease</i> , 2022, 42, 327-340.	3.6	1
323	Thriving in turbulent times: EASL reflects on 2021, looking to 2022 and beyond. <i>Journal of Hepatology</i> , 2022, 77, 278-281.	3.7	1
324	Reply. <i>Hepatology</i> , 2014, 60, 1449-1450.	7.3	0

#	ARTICLE	IF	CITATIONS
325	Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. Liver International, 2015, 35, 2275-2284.	3.9	0
326	Reply. Hepatology, 2016, 63, 1052-1053.	7.3	0
327	Reply to: "Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?" Journal of Hepatology, 2018, 68, 611-612.	3.7	0
328	From the Editor's desk. Journal of Hepatology, 2018, 69, 1209-1212.	3.7	0
329	Editorial: moving towards a robust definition of sarcopenia in cirrhosis"authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 341-342.	3.7	0
330	From the Editor's desk. Journal of Hepatology, 2019, 70, 1039-1042.	3.7	0
331	From the Editor's desk. Journal of Hepatology, 2019, 71, 1-4.	3.7	0
332	From the Editor's desk. Journal of Hepatology, 2019, 70, 583-586.	3.7	0
333	From the Editor's desk. Journal of Hepatology, 2019, 70, 819-821.	3.7	0
334	Reply to: Correspondence on "the times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy." Journal of Hepatology, 2021, 75, 1499-1501.	3.7	0
335	Hepatology (l). , 2010, , 500-546.		0
336	Entzündliche Lebererkrankungen. , 2015, , 303-349.		0
337	Reply to: "G-CSF in acute-on-chronic liver failure " Art of "patient selection" is paramount! Journal of Hepatology, 2022, 76, 473-475.	3.7	0
338	Benigne und maligne Neoplasien der Leber. , 2007, , 921-929.		0
339	Autoantibody formation against a canalicular epitope found in a patient with acute intrahepatic cholestasis with PFIC-like presentation. JHEP Reports, 2022, 4, 100418.	4.9	0
340	Gadoxetic Acid-Based MRI for Decision-Making in Hepatocellular Carcinoma Employing Perfusion Criteria Only" A Post Hoc Analysis from the SORAMIC Trial Diagnostic Cohort. Current Oncology, 2022, 29, 565-577.	2.2	0
341	Evaluation of Inhibitory Antibodies against the Muscarinic Acetylcholine Receptor Type 3 in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Journal of Clinical Medicine, 2022, 11, 681.	2.4	0
342	End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients. Journal of Microbiology, Immunology and Infection, 2022, , .	3.1	0